metformin has been researched along with Experimental Hepatoma in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin treatment decreased ATXN7L3B-induced tumor-initiating ability in a HCC mouse model, implying that metformin may inhibit cancer stemness by downregulating ATXN7L3B." | 5.62 | ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. ( Cao, N; Cha, JH; Chen, B; Yan, M; Yan, X; Yang, WH; Ye, P, 2021) |
| "Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile." | 5.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family." | 5.40 | Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. ( Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Kurokohchi, K; Maeda, E; Masaki, T; Mimura, S; Miyoshi, H; Mori, H; Morishita, A; Murao, K; Nomura, T; Okano, K; Sakamoto, T; Suzuki, Y; Tani, J; Toyota, Y; Yoneyama, H, 2014) |
| "Metformin treatment decreased ATXN7L3B-induced tumor-initiating ability in a HCC mouse model, implying that metformin may inhibit cancer stemness by downregulating ATXN7L3B." | 1.62 | ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin. ( Cao, N; Cha, JH; Chen, B; Yan, M; Yan, X; Yang, WH; Ye, P, 2021) |
| "Metformin is a hypoglycaemic agent used to treat type 2 diabetes mellitus (DM2) patients, with a broad safety profile." | 1.51 | Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. ( Callegari, E; Gramantieri, L; Guerriero, P; Negrini, M; Pinton, P; Rimessi, A; Sabbioni, S; Shankaraiah, RC; Silini, EM, 2019) |
| "Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family." | 1.40 | Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. ( Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Kurokohchi, K; Maeda, E; Masaki, T; Mimura, S; Miyoshi, H; Mori, H; Morishita, A; Murao, K; Nomura, T; Okano, K; Sakamoto, T; Suzuki, Y; Tani, J; Toyota, Y; Yoneyama, H, 2014) |
| "Metformin was also effective in significantly enhancing insulin binding in both IM-9 and MCF-7 cells." | 1.26 | Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells. ( Goldfine, ID; Pezzino, V; Vigneri, R; Wong, KY, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mamdouh, AM | 1 |
| Khodeer, DM | 1 |
| Tantawy, MA | 1 |
| Moustafa, YM | 1 |
| Shankaraiah, RC | 1 |
| Callegari, E | 1 |
| Guerriero, P | 1 |
| Rimessi, A | 1 |
| Pinton, P | 1 |
| Gramantieri, L | 1 |
| Silini, EM | 1 |
| Sabbioni, S | 1 |
| Negrini, M | 1 |
| Luo, C | 1 |
| Liang, J | 1 |
| Sharabi, K | 1 |
| Hatting, M | 1 |
| Perry, EA | 1 |
| Tavares, CDJ | 1 |
| Goyal, L | 1 |
| Srivastava, A | 1 |
| Bilodeau, M | 1 |
| Zhu, AX | 1 |
| Sicinski, P | 1 |
| Puigserver, P | 1 |
| Jin, Z | 1 |
| Jia, BX | 1 |
| Tan, LD | 1 |
| Chen, QM | 1 |
| Liu, YH | 1 |
| Chen, B | 1 |
| Cha, JH | 1 |
| Yan, M | 1 |
| Cao, N | 1 |
| Ye, P | 1 |
| Yan, X | 1 |
| Yang, WH | 1 |
| Miyoshi, H | 1 |
| Kato, K | 1 |
| Iwama, H | 1 |
| Maeda, E | 1 |
| Sakamoto, T | 1 |
| Fujita, K | 1 |
| Toyota, Y | 1 |
| Tani, J | 1 |
| Nomura, T | 1 |
| Mimura, S | 1 |
| Kobayashi, M | 1 |
| Morishita, A | 1 |
| Kobara, H | 1 |
| Mori, H | 1 |
| Yoneyama, H | 1 |
| Deguchi, A | 1 |
| Himoto, T | 1 |
| Kurokohchi, K | 1 |
| Okano, K | 1 |
| Suzuki, Y | 1 |
| Murao, K | 1 |
| Masaki, T | 1 |
| Purushotham, A | 1 |
| Tian, M | 1 |
| Belury, MA | 1 |
| Vigneri, R | 2 |
| Pezzino, V | 2 |
| Wong, KY | 1 |
| Goldfine, ID | 2 |
| Solomon, SS | 1 |
| Mishra, SK | 1 |
| Cwik, C | 1 |
| Rajanna, B | 1 |
| Postlethwaite, AE | 1 |
| Purrello, F | 1 |
| Gullo, D | 1 |
| Buscema, M | 1 |
10 other studies available for metformin and Experimental Hepatoma
| Article | Year |
|---|---|
In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Amygdalin; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogen | 2021 |
Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease M | 2019 |
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency.
Topics: Animals; Antineoplastic Agents; Cyclin D1; Cyclin-Dependent Kinase 4; Diabetes Mellitus, Type 2; Hyp | 2020 |
Combination therapy with metformin and IL-12 to inhibit the growth of hepatic carcinoma by promoting apoptosis and autophagy in HepG2-bearing mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Down-Regulation; Female; Humans; Hypoglycemic A | 2021 |
Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Gene Expres | 2014 |
The citrus fruit flavonoid naringenin suppresses hepatic glucose production from Fao hepatoma cells.
Topics: Animals; Dose-Response Relationship, Drug; Flavanones; Glucose; Glucose-6-Phosphatase; Hypoglycemic | 2009 |
Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells.
Topics: Animals; Biguanides; Breast Neoplasms; Cell Line; Female; Fibroblasts; Humans; Insulin; Liver Neopla | 1982 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 1997 |
Metformin enhances certain insulin actions in cultured rat hepatoma cells.
Topics: Aminoisobutyric Acids; Animals; Biological Transport; Cell Line; Drug Synergism; Glucose; Glycogen; | 1988 |